The current performance-linked and risk sharing agreement scene in the Spanish region of Catalonia.
Expert Rev Pharmacoecon Outcomes Res
; 19(6): 743-748, 2019 Dec.
Article
in En
| MEDLINE
| ID: mdl-30821532
ABSTRACT
Background:
Traditional drug payment schemes in Catalonia are generally based on the negotiation of fixed prices; however, disadvantages arise in the case of innovative therapies. Risk sharing agreements distribute potential health and economic uncertainties and high prices on access across the interested parts.Objectives:
To identify, characterize and analyze current publicly available agreement reports signed by the Catalan Health Service and different pharmaceutical companies evaluating the current market access scene for new drugs in Catalonia.Methods:
A database of agreements implemented between 2013 and 2018 was developed by using publicly available data. Data analysis was performed in a descriptive way, presenting summaries in datasheets.Results:
A total of 7 managed entry agreements were analyzed. Two extensions regarding previous agreements were also taken into account. The main involved disease area is oncology (57%) and the most common length is 1 year, whereas the longest is 3 years.Conclusions:
Managed entry agreements are gaining popularity and are viewed as positive schemes by stakeholders, payers and health services, leading to a general increase of accords during the last years. However, there are hardly any studies regarding the impact of RSA post-implementation, a field of great relevance regarding health policies.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Drug Costs
/
Risk Sharing, Financial
/
Drug Industry
Type of study:
Etiology_studies
/
Health_economic_evaluation
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Humans
Country/Region as subject:
Europa
Language:
En
Journal:
Expert Rev Pharmacoecon Outcomes Res
Journal subject:
FARMACOLOGIA
Year:
2019
Document type:
Article
Affiliation country:
España